Carbamazepine--a double-blind comparison with phenytoin.
In a double-blind crossover study, carbamazepine and phenytoin were compared as single anticonvulsants in 47 patients with focal and major generalized seizures. Each drug provided superior seizure control in about half the patients, but significantly fewer patients had objective side effects while taking carbamazepine. Neuropsychologic testing showed improved performance in cognitive function and emotional status of patients while and carbamazepine. No hematotoxic complications arose, but vigilant follow-up is advised. Mean serum level of carbamazepine was 9.3 microng per milliliter with a suggested therapeutic range of 8 to 12 microng per milliliter reached by eventual doses of 16 to 20 mg per kilogram. Carbamazepine offers an independent choice of improved seizure control with a possibility of fewer side effects.
D000328:Adult; D001259:Ataxia / Q000139:chemically induced; D002220:Carbamazepine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006400:Hematocrit; D006801:Humans; D007958:Leukocyte Count; D010672:Phenytoin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D002220:Carbamazepine; D010672:Phenytoin